Enavate Sciences

Normunity is a biotechnology company focused on developing a new class of precision immuno-oncology medicines known as immune normalizers. These innovative therapies aim to restore the body's natural immune response against cancer by targeting novel mechanisms that disrupt immune function. Normunity collaborates closely with the lab of Dr. Lieping Chen at Yale School of Medicine, leveraging proprietary discovery platforms to explore complex interactions between cancer and the immune system. The company's emerging pipeline includes drug programs designed to address the exclusion of T-cells from immune-sensitive tumors and other factors that impede normal immune activity in cancer patients. Normunity operates from locations in Boston, Massachusetts, and West Haven, Connecticut.

Aviceda Therapeutics is a late-stage pre-clinical biotechnology company focused on developing innovative therapies for glyco-immune diseases. The company leverages glycobiology and a proprietary cell-based high-throughput screening platform to create next-generation immunomodulators that target the innate immune system and address chronic non-resolving inflammation. Aviceda’s therapeutic pipeline includes a range of products aimed at various conditions, such as dry eye, diabetic retinopathy, retinoblastoma, and other diseases in the fields of oncology, neurology, and fibrosis. The company’s approach combines advanced biological insights with cutting-edge nanoparticle technology, enabling the development of targeted treatments designed to improve patient outcomes.

OrsoBio is a clinical-stage biopharmaceutical company focused on developing innovative therapies to treat severe metabolic disorders such as obesity, type 2 diabetes, lipodystrophies, and severe dyslipidemia. The company aims to restore energy homeostasis in patients by targeting pathways relevant to maintaining energy balance, thereby addressing the root causes of these conditions. OrsoBio's pipeline includes therapies intended to revolutionize the treatment of these disorders.

BridgeBio Oncology Therapeutics is a biopharmaceutical company specializing in the development of precision oncology therapeutics. It focuses on targeting RAS-dependent cancers, leveraging a profound understanding of RAS signaling biology to create drugs that selectively inhibit RAS-driven PI3K activation and a wide spectrum of KRAS mutants. The company aims to provide patients with tailored treatments that address both active and inactive cancer-driving states.

Sionna Therapeutics was formed in late 2019, leveraging 10 years of large pharma scientific investment and expertise. Our experienced scientific team has been on a mission to fully normalize CFTR function. In the three decades since the discovery of the genetic defects that cause cystic fibrosis (CF), researchers have made remarkable advances for patients. Yet the ultimate goal of CF drug development – to fully normalize the function of CFTR, the key protein leading to the pathology of CF – has remained out of reach.

Sudo Biosciences is a biopharmaceutical company focused on designing and developing innovative medicines that target the tyrosine kinase 2 (TYK2) pseudokinase domain. This domain plays a vital role in cytokine signaling pathways associated with various immune-mediated inflammatory conditions. Sudo Biosciences has a pipeline of next-generation TYK2 inhibitors, including a candidate aimed at treating multiple sclerosis and neurodegenerative diseases characterized by neuroinflammation, as well as a topical treatment for immune-mediated dermatologic diseases. The company's mission is to provide effective therapies for patients at competitive costs, thereby transforming their lives and addressing unmet medical needs.

Graviton Bioscience is a clinical-stage drug discovery and development firm focused on creating and developing therapies for the treatment of CNS, autoimmune, fibrotic, and other significant disorders in which ROCK2 plays a critical role in pathology.

Sudo Biosciences is a biopharmaceutical company focused on designing and developing innovative medicines that target the tyrosine kinase 2 (TYK2) pseudokinase domain. This domain plays a vital role in cytokine signaling pathways associated with various immune-mediated inflammatory conditions. Sudo Biosciences has a pipeline of next-generation TYK2 inhibitors, including a candidate aimed at treating multiple sclerosis and neurodegenerative diseases characterized by neuroinflammation, as well as a topical treatment for immune-mediated dermatologic diseases. The company's mission is to provide effective therapies for patients at competitive costs, thereby transforming their lives and addressing unmet medical needs.

OrsoBio is a clinical-stage biopharmaceutical company focused on developing innovative therapies to treat severe metabolic disorders such as obesity, type 2 diabetes, lipodystrophies, and severe dyslipidemia. The company aims to restore energy homeostasis in patients by targeting pathways relevant to maintaining energy balance, thereby addressing the root causes of these conditions. OrsoBio's pipeline includes therapies intended to revolutionize the treatment of these disorders.

Immunome Inc., founded in 2006 and headquartered in Exton, Pennsylvania, is a biotechnology company focused on discovering, developing, and commercializing highly targeted and native human cancer antibodies against universal cancer antigens. The company utilizes its proprietary RealMAb technology to identify novel antigens and the corresponding native human antibodies that target them. Additionally, Immunome employs ScreenMab multiplex functional screening technology to pinpoint monoclonal antibodies with high specificity for tumor neoantigens.

Upstream Bio Inc is a clinical-stage biotechnology company dedicated to developing treatments for inflammatory diseases, particularly severe respiratory disorders. The company's primary focus is on verekitug, an antibody therapy designed to inhibit the Thymic Stromal Lymphopoietin receptor. This receptor is a key target in the inflammatory response, influencing various immune cells and signaling pathways involved in both common and rare illnesses. By targeting TSLP, Upstream Bio aims to address the underlying mechanisms of severe asthma and related conditions, positioning itself as a significant player in the field of immunotherapy.

Compass Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative antibody therapeutics for the treatment of solid tumors and hematological malignancies. Founded in 2014 and headquartered in Cambridge, Massachusetts, the company utilizes its proprietary StitchMabs and common light-chain platforms to discover and create multispecific antibody combinations. Its lead product candidate, CTX-471, is an agonistic monoclonal antibody targeting CD137, currently undergoing Phase 1 clinical trials in patients with prior PD-1/PD-L1 checkpoint inhibitor treatment. Another significant candidate, CTX-009, is a bispecific antibody that inhibits DLL4-mediated Notch signaling and VEGF-A signaling, having completed a Phase 1 dose escalation study. Additionally, CTX-8371, a bispecific antibody targeting PD-1 and PD-L1, is in the IND-enabling stage. Through its innovative approaches, Compass Therapeutics aims to enhance immune engagement and improve therapeutic outcomes for cancer patients.

CAMP4 Therapeutics Corporation is a bioinformatics company founded in 2015 and based in Cambridge, Massachusetts. The company specializes in gene regulation circuitry, focusing on the fundamental causes of diseases by manipulating gene expression. Utilizing its proprietary 4-D gene circuitry platform, CAMP4 codifies the activation of approximately 24,000 human genes into a discrete set of combinatorial rules based on existing cellular signaling pathways. This innovative approach allows CAMP4 to effectively control gene production, thereby accelerating the development of new therapies. By employing this technology, the company aims to streamline the drug development process, significantly reducing both the time and risks associated with bringing new medicines to patients.